You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥(06996.HK)夥藥明生物(02269.HK)等加快抗體偶聯藥物研發生產
阿思達克 02-01 15:05
德琪醫藥(06996.HK)公布,與藥明生物(02269.HK)及合全藥業三方達成戰略合作,共同加快抗體偶聯藥物(ADC)的研發及生產,通過「平台+自研」並行策略,以提高ADC藥物等早期研發項目的孵化效率。

藥明生物與合全藥業將為德琪醫藥ADC藥物開發提供產品中間體的規模放大、工藝開發和GMP生產服務,其中德琪醫藥專注於抗體偶聯藥物的核心單克隆抗體(mAb)的研發;合全藥業專注於連接體和有效載荷的GMP生產;藥明生物專注mAb、生物偶聯和成品凍乾工藝開發,並以GMP標準生產偶聯原液和凍乾製劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account